TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26303505

Group type: EXPERIMENTAL
Intervention: Enhanced Strength Training (EST) program with motivationally-tailored behavioral counselling
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Enhanced Strength Training (EST) program
Number of subjects: 318

Group type: COMPARATOR
Intervention: Standard Strength Training (SST) program
Number of subjects: 318
Study: 23593327

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg orally thrice daily for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20621562

Group type: EXPERIMENTAL
Intervention: Continue antihypertensive drugs
Number of subjects: 763

Group type: COMPARATOR
Intervention: Stop antihypertensive drugs
Number of subjects: 763
Study: 18855822

Group type: EXPERIMENTAL
Intervention: counseling + methadone
Number of subjects: 211

Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 211

Group type: COMPARATOR
Intervention: counseling + transfer
Number of subjects: 211
Study: 15837248

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting TAXUS stent
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Bare-metal equivalent stent
Number of subjects: 1314
Study: 12067045

Group type: EXPERIMENTAL
Intervention: Dietary intervention (not specified in detail)
Number of subjects: 3084
Study: 10502591

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization
Number of subjects: 192

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 192
Study: 8904857

Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy (albuterol or ipratropium bromide)
Number of subjects: 8
Study: 1872596

Group type: COMPARATOR
Intervention: Placebo (lactose tablets)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyridoxine + ascorbic acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyridoxine + iron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyridoxine + riboflavin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multivitamin supplements
Number of subjects: 60
Study: 6315982

Group type: EXPERIMENTAL
Intervention: 5 g of guar gum
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31144427

Group type: EXPERIMENTAL
Intervention: Vildagliptin in combination with metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29564872

Group type: EXPERIMENTAL
Intervention: 8% omega-ceramides, hydrophilic sugars, 5% niacinamide cream applied twice daily (group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily (group B)
Number of subjects: 27
Study: 27387214

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (BP RF) applied to 36 patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency (MP RF) applied to 35 patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BP RF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency (MP RF)
Number of subjects: 71
Study: 24798767

Group type: EXPERIMENTAL
Intervention: 20 mg zinc supplementation for 24 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22752960

Group type: EXPERIMENTAL
Intervention: Computerized working memory training (adaptive)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo condition (nonadaptive)
Number of subjects: 26
Study: 20362710

Group type: EXPERIMENTAL
Intervention: 400 mg of EPA + DHA and 2 g of ALA
Number of subjects: 4837

Group type: COMPARATOR
Intervention: Placebo (margarine spread without EPA + DHA and ALA)
Number of subjects: 4837
Study: 16865379

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 40
Study: 16767436

Group type: EXPERIMENTAL
Intervention: PRO-B (0.3 g/kg protein before RT + placebo after RT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PRO-A (placebo before + protein after RT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PLA (placebo before and after RT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups (PRO-B, PRO-A, PLA)
Number of subjects: 29
Study: 14570668

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10891984

Group type: EXPERIMENTAL
Intervention: Normal-appearing white matter (NAWM) in patients with MS
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MS lesions (173 identified lesions)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Enhancing lesions (22 lesions)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: T1-hypointense lesions (60 lesions)
Number of subjects: 35

Group type: COMPARATOR
Intervention: NAWM
Number of subjects: 35
Study: 8847861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 240 mg diltiazem OD
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 300 mg diltiazem OD
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 360 mg diltiazem OD
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 420 mg diltiazem OD
Number of subjects: 138
Study: 1562095

Group type: EXPERIMENTAL
Intervention: SAT-1 (Edwards)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SAT-2 (Baxter, Edwards Division)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hemopro2 (Spectramed)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oximetrix 3 (Abbott)
Number of subjects: 80
Study: 6320945

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid rich oil (fish oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eicosapentaenoic acid poor oil (corn/olive oil)
Number of subjects: 0
Study: 30581138

Group type: EXPERIMENTAL
Intervention: Combined physical activity and fall prevention intervention (one physiotherapist visit, fortnightly telephone-based health coaching, a pedometer, tailored fall prevention advice, and a fall prevention brochure)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (received the same fall prevention brochure)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Combined physical activity and fall prevention intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study: 30165465

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT; N = 181)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC; N = 173)
Number of subjects: 354
Study: 27042750

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment for 2 years
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment with 25(OH)D above the 50th percentile
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment with 25(OH)D below the 50th percentile
Number of subjects: 57
Study: 24201089

Group type: EXPERIMENTAL
Intervention: Evening walking group (30 min/day or more on at least 5 days/week for 12 weeks)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Morning walking group (30 min/day or more on at least 5 days/week for 12 weeks)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no walking intervention)
Number of subjects: 330
Study: 22454414

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² IV over 1 hour for 21 days plus prednisone 5 mg orally twice per day plus bevacizumab 15 mg/kg IV every 3 weeks (DP + B)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² IV over 1 hour for 21 days plus prednisone 5 mg orally twice per day (DP)
Number of subjects: 1050
Study: 20064492

Group type: EXPERIMENTAL
Intervention: Cued gait training with external rhythmical cues (auditory, visual, and somatosensory) for 3 weeks
Number of subjects: 153
Study: 19226894

Group type: EXPERIMENTAL
Intervention: Acupuncture at Huatuojiaji points
Number of subjects: 56

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 56
Study: 16152868

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 12490735

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg monthly by intramuscular injection
Number of subjects: 851

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 851

Group type: COMPARATOR
Intervention: Fulvestrant and Anastrozole
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 851

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 851
Study: 10718489

Group type: EXPERIMENTAL
Intervention: Oophorectomy plus tamoxifen
Number of subjects: 482

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study: 8967879

Group type: EXPERIMENTAL
Intervention: PE‐PEUG (new polyurethane vascular access graft)
Number of subjects: 52

Group type: COMPARATOR
Intervention: E‐PTFEG (expanded polytetrafluoroethylene graft)
Number of subjects: 52
Study: 1938279

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6749827

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 31969301

Group type: EXPERIMENTAL
Intervention: Simvastatin 1% gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin 1% mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 28360116

Group type: EXPERIMENTAL
Intervention: 0.8-mg folic acid and 10-mg enalapril
Number of subjects: 20424

Group type: COMPARATOR
Intervention: 10-mg enalapril only
Number of subjects: 20424
Study: 26616535

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention (Second Life)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Phone conference call intervention
Number of subjects: 202
Study: 24038736

Group type: EXPERIMENTAL
Intervention: No tumor spill
Number of subjects: 499

Group type: COMPARATOR
Intervention: Tumor spill
Number of subjects: 499
Study: 22004512

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 2 kcal/min (G2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 4 kcal/min (G4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 1 kcal/min (G1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion
Number of subjects: 8
Study: 19223626

Group type: EXPERIMENTAL
Intervention: EDP-420 (100-1200 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EDP-420 (400 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EDP-420
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17961376

Group type: EXPERIMENTAL
Intervention: Selective‐adrenoceptor antagonists (terazosin, doxazosin, tamsulosin, naftopidil)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: 5 alpha‐reductase inhibitors (finasteride, epristeride)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Natural product (cernilton)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Naftopidil
Number of subjects: 906
Study: 16307631

Group type: EXPERIMENTAL
Intervention: Case version A (with clues to suggest limited patient literacy skills)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Case version B (without clues to suggest limited patient literacy skills)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: General educational strategies recommended for preventing readmission
Number of subjects: 98
Study: 12486870

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg elemental calcium per day for 2 months)
Number of subjects: 15
Study: 9655592

Group type: EXPERIMENTAL
Intervention: Field-dependent teaching approach
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination teaching approach
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overall student satisfaction
Number of subjects: 42
Study: 7864689

Group type: EXPERIMENTAL
Intervention: disease modifying antirheumatic drug therapy
Number of subjects: 190
Study: 2700102

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 25
Study: 1093613

Group type: EXPERIMENTAL
Intervention: Simplified computer-aided diagnosis system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Withdrawal of computer feedback
Number of subjects: 0
Study: 31154811

Group type: EXPERIMENTAL
Intervention: Vialogues intervention (12-monthly HIV/STI prevention educational sessions)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vialogues intervention
Number of subjects: 76
Study: 31109343

Group type: EXPERIMENTAL
Intervention: Monitoring and feedback system for staff behaviour during surgical procedures
Number of subjects: 9945

Group type: COMPARATOR
Intervention: Control group (blinded to monitoring data and quality improvement approaches)
Number of subjects: 9945
Study: 27865566

Group type: EXPERIMENTAL
Intervention: Higher phosphorus intake for 3 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lower phosphorus intake for 3 weeks
Number of subjects: 31
Study: 25582031

Group type: COMPARATOR
Intervention: Smiths Medical Jelco (human use) catheter
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Abbott Animal Health catheter (veterinary use)
Number of subjects: 69
Study: 22902362

Group type: EXPERIMENTAL
Intervention: Thalidomide plus Zoledronic Acid (Thal/ZLD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Zoledronic Acid alone (ZLD)
Number of subjects: 68
Study: 21848879

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19219847

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16919322

Group type: EXPERIMENTAL
Intervention: Jumpstart, a motivationally tailored, print based intervention (n = 95)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Choose to Move, a self‐help printed booklet (n = 93)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Wellness, women's health materials (n = 92)
Number of subjects: 280
Study: 15309445

Group type: EXPERIMENTAL
Intervention: Slow release vitamin C (2 x 250 mg daily) with vitamin E (2 x 91 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plain release vitamin C (2 x 250 mg daily) with vitamin E (2 x 91 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15079004

Group type: EXPERIMENTAL
Intervention: Triflusal 600 mg daily
Number of subjects: 431

Group type: COMPARATOR
Intervention: Aspirin 325 mg daily
Number of subjects: 431
Study: 10512212

Group type: EXPERIMENTAL
Intervention: Early controlled range of motion training using an Air‐Cast ankle brace (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cast immobilization in a below‐knee plaster for 6 weeks (Group A)
Number of subjects: 30
Study: 8529078

Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 0
Study: 2318105

Group type: EXPERIMENTAL
Intervention: High-carbohydrate low-fat diet (60% CHO, 20% fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-carbohydrate high-fat diet (40% CHO, 40% fat)
Number of subjects: 8
Study: 419761

Group type: EXPERIMENTAL
Intervention: Hexestrol treatment for 12 months or longer
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (179 women)
Number of subjects: 176
Study: 30991824

Group type: EXPERIMENTAL
Intervention: Psychoeducation regarding 'forgetfulness' and screening for cognitive impairment
Number of subjects: 18
Study: 27167152

Group type: EXPERIMENTAL
Intervention: CRC screening invitation
Number of subjects: 10271

Group type: COMPARATOR
Intervention: Control group (not invited for CRC screening)
Number of subjects: 10271

Group type: EXPERIMENTAL
Intervention: Demographic factors (gender)
Number of subjects: 10271

Group type: EXPERIMENTAL
Intervention: Demographic factors (education level)
Number of subjects: 10271
Study: 26088721

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS) 40 μg/dose
Number of subjects: 604

Group type: COMPARATOR
Intervention: Morphine intravenous (i.v.) patient-controlled analgesia (PCA) 1 mg/dose
Number of subjects: 604
Study: 24997439

Group type: EXPERIMENTAL
Intervention: 6-lesson clinician-guided iCBT program
Number of subjects: 99

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 99
Study: 22234398

Group type: EXPERIMENTAL
Intervention: Passive knee rotation (flexion and extension)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static knee position at 10°
Number of subjects: 0
Study: 19912069

Group type: EXPERIMENTAL
Intervention: Oral PR oxycodone/naloxone
Number of subjects: 985

Group type: COMPARATOR
Intervention: Oral PR oxycodone
Number of subjects: 985

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985
Study: 17893165

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 powder
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15034826

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (20 mg/kg per day; maximum dose, 1000 mg/day) for 5 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (75 mg/day; maximum dose, 2.5 g/day) for 5 days
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone
Number of subjects: 149
Study: 12118266

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9428871

Group type: EXPERIMENTAL
Intervention: Gasless, retractor group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional CO2 pneumoperitoneum group (CPP)
Number of subjects: 26
Study: 8087385

Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler (Turbuhaler)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pressurized aerosol (aerosol device)
Number of subjects: 9
Study: 2571502

Group type: EXPERIMENTAL
Intervention: Saccadic reaction times in acute schizophrenics
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Saccadic reaction times in remitted schizophrenics
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (normal volunteers)
Number of subjects: 47
Study: 31092706

Group type: EXPERIMENTAL
Intervention: Epidural waveform analysis through the needle (EWA-N)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epidural waveform analysis through the catheter (EWA-C)
Number of subjects: 120
Study: 28620779

Group type: EXPERIMENTAL
Intervention: Tailored DXA result letter and educational bone health brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 7749
Study: 25306213

Group type: EXPERIMENTAL
Intervention: Parental limits on TV viewing time
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Parental limits on TV programming content
Number of subjects: 816
Study: 25799808

Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg/kg/day) for 7 days
Number of subjects: 204

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 204
Study: 22851554

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of course one of therapy
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Control group (no GO)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Meta-analysis of 2,228 patients in two UK trials
Number of subjects: 1115
Study: 19231545

Group type: EXPERIMENTAL
Intervention: Real interferential therapy (IFT) sessions, 12 sessions over a 4-week period.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo IFT sessions, 12 sessions over a 4-week period.
Number of subjects: 26
Study: 17551146

Group type: EXPERIMENTAL
Intervention: Mass spectrometry-derived proteomic signature of 25 signals
Number of subjects: 58
Study: 15179026

Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.85 mg DMT/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 18
Study: 11296131

Group type: EXPERIMENTAL
Intervention: Combination therapies of purine analogues (pentostatin, fludarabine, cladribine) and monoclonal antibodies (rituximab, CAMPATH I‐H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies designed to induce high-quality responses
Number of subjects: 0
Study: 9496710

Group type: COMPARATOR
Intervention: Healthy control subjects (n=6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patients with end-stage heart failure (n=10)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Net extraction of NOx across the heart
Number of subjects: 16
Study: 8044980

Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen sodium ophthalmic solution
Number of subjects: 105

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 105
Study: 3058657

Group type: EXPERIMENTAL
Intervention: 60.0 Gy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 64.8 Gy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 69.6 Gy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison with RTOG Protocol 71‐04 (60 Gy in 30 fractions in 6 weeks)
Number of subjects: 50
Study: 31898512

Group type: EXPERIMENTAL
Intervention: CBT intervention app (SPARX)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Second CBT app (Sleep Ninja)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 10000
Study: 30691980

Group type: EXPERIMENTAL
Intervention: 4CMenB booster dose
Number of subjects: 4

Group type: COMPARATOR
Intervention: 2 catch-up doses of 4CMenB (vaccine-naïve)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (Primed_4y and Primed_7.5y)
Number of subjects: 4

Group type: COMPARATOR
Intervention: 4CMenB vaccine (Naïve_4y and Naïve_7.5y)
Number of subjects: 4
Study: 28072797

Group type: EXPERIMENTAL
Intervention: Pregabalin (150, 300, 600, and flexible 150-600 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant NeP medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0